Dismantle the United Nations and the World Health Organization



Research shows that after WWII, the Rockefellers needed to create the ideal political framework if their monopolies over oil and the drug/medicine business were to survive. With the assistance of the Rockefeller influence, in 1945, the United Nations was founded in San Francisco. In addition, founded as organizations that purportedly were created to serve the well-being of the people, the UN created subsidiary organizations including the World Health Organization (WHO) and the World Trade Organization (WTO), which soon turned out to be nothing more than the political arms of the global oil and drug interests.

 In 1963, under the pretense of protecting the health of consumers, the United Nations was instrumental in launching a four decade battle to outlaw natural health products, including vitamins and other non-patentable approaches to health. The ultimate goal, was to eliminate all competition for the soon to be multi-billion dollar drug enterprise. This (criminal) global strategy monopolized the health for billions of people, by providing lethal pills while depriving access to lifesaving information about the health benefits of natural products. 

Between 1990-1992, Dr. Rath identified micronutrient deficiency as a primary cause for most diseases, including heart attacks, high blood pressure, diabetic circulatory problems, cancer and autoimmune disorders said to be caused from an unknown source with no known cures. 

The World Health Organization (WHO) was established in 1948 as a specialized agency of the UN to serve as the authority for directing and coordinating international health matters and public health in general It is said that WHO fulfills these responsibilities through its extensive programme of publications.  That's all it has to do? Support Big Pharma research that further supports its goal of monopolization? 

Consider the latest 2016 publication sponsored by WHO and written by the Department of Mental Health and Substance Abuse entitled "The health and social effects of non medical cannabis use" .This publication is lacking in reporting current information as it reports that the long-term health effects of cannabis use includes mental disorders including psychoses, depression, anxiety and suicide behavior; cardiovascular disease; chronic obstructive pulmonary disease, respiratory disease and cancer. Ironically, a number of patent applications have been filed using cannabis to treat the above disorders. 

This publication also reports the harmful effects of cannabis-use disorder.  Cannabis use disorder is defined in the fifth revision of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5)   as the "continued use of cannabis despite clinically significant impairment, ranging from mild to severe." It is reported that no medication has been proven effective in treating cannabis use disorder, however, most recently, the synthetic version of THC, known as Dronabinol, has been considered as an effective medication for cannabis use disorder. As an aside, controlled studies on Dronabinol use has been shown to create the negative effects reported as being associated with the use of the whole plant. 

Antipsychotic drugs produced by Big-Pharma, are prescribed to children at alarming rates, without studying the long-term effects, despite FDA black box warnings. Most antipsychotic medication use among children and adolescents is “off label”, that is, for indications that are not approved by the FDA or used for children who are younger than the approved age ranges.

Conversely, cannabis is considered a controlled substance under Schedule I of the CSA in the US - where it is considered 'to have a high potential for abuse, no currently accepted medical use in treatment and a lack of accepted safety standards for using the drug or other substance under medical supervision.'

The WHO's most recent study (noted above) and its emphasis on "cannabis use disorder" is contrary to fundamental justice including the principles of "overbreadth" and "arbitrary" with respect to rejecting herbal medicine in favor of  harmful pharmaceutical pills.  

The WHO, in pursuing their objective of "shaping the research agenda and stimulating the translation and dissemination of valuable knowledge" is overbroad in supporting harmful pharmaceutical pills while vilifying cannabis consumption with incorrect and faulty information to the public at large.











Cannabinoid patents



Although the cannabinoids THC and CBD are the only two cannabinoids required to be disclosed by the Licensed Producers under Canada's marijuana legislation, some dispensaries in the US also only disclose these two cannabinoids in their strains, choosing to ignore the following cannabinoids that have a greater presence over CBD in Indica strains: 


Cannabigerol (CBG) - the link for this cannabinoid is for a patent application filed by GW Pharmaceuticals in treating depression and other mood disorders. 

CBG for a number of diseases - the diseases or conditions to be treated are taken from the group: pain, neurodegenerative disease, ischemic disease, brain injury or damage, acquired brain injury, age related inflammatory or autoimmune disease, cachexia, nausea and vomiting, glaucoma, movement disorders, rheumatoid arthritis, asthma, allergy, psoriasis, Crohn's disease, systemic lupus erythematosus, diabetes, cancer, osteoporosis, renal ischemia and nephritis.  This was filed by GW Pharma

Cannabichromene (CBC) - GW Pharma claims to have invented a method for extracting this cannabinoid

CBC and Terpenes  - GW's invention in this patent is in the treatment of cancer  where the use of at least 50% of the phytocannabinoid component is not THC or CBD but CBC and with at least 15% of the non-phytocannabinoid containing component comprising certain terpenes such as myrcene and pinene. 

CBC as an antiinflammatory and antimicrobial  - filed by the University of Mississippi

Tetrahydrocannabivarin (THCV) -  by GW Pharma - using THCV for the treatment of obesity, schizophrenia, epilepsy, Alzheimer's, bone disorders, bulimia or the treatment of drug, alcohol or nicotine abuse or dependency

THCV, CBG, CBC and/or CBDV for intestinal inflammatory diseases -  this patent application filed by GW Pharma is for any one of the named cannabinoids for the preferential treatment of either ulcerative colitis or Crohn's disease


The above patents are just a drop in the bucket relative to the number of studies conducted and patent applications filed using cannabis's medicinal properties.